Compare Lennar Corporation (LEN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Sana Biotechnology Inc — how do they compare? Lennar Corporation trades at $81.84 (market cap $19.92B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Lennar Corporation is far larger — about 22.8× Sana Biotechnology Inc's market cap, and Lennar Corporation pays a 2.41% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LEN | SANA | |
|---|---|---|
Market Cap | $19.92B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $5.92 |
52-Week Low | $82.30 | $2.68 |
Enterprise Value | $23.80B | $848.03M |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $81.84, down 2.44% today, near its 52-week low of $81.18. The stock shows bearish technical signals with recent earnings misses and declining profitability margins. Revenue fell to $34.19B in 2025 with net income dropping to $2.08B. Positive catalysts include a favorable housing bill and analyst consensus price target of $84.78, suggesting modest upside from current levels.
LEN presents a value opportunity with low P/E (12.99) and P/B (0.92) ratios, but faces headwinds from housing affordability and rising mortgage rates. Execution on margin recovery and volume growth is critical. Risks include persistent earnings pressure and macroeconomic sensitivity. Institutional sentiment is mixed with 46% buy ratings amid cautious outlook.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
